HepCBC Mission Statement
HepCBC is a non-profit organization run by and for people infected and affected by viral hepatitis. Our mission is to provide education, prevention and support to those living with viral hepatitis.
Hot Off The Press!
Friday, Feb. 22, 2019 News Recap: Time to Change Protocols for Post-SVR Monitoring for Liver Cancer? In Memoriam: Anita York (May 27, 1953 - Feb. 7, 2019) Funding via “Womens Wellness & Leadership Project” for women in BC living with HCV (&/or HIV) MAVIRET™ 8 week, pan-genotypic HCV treatment, good for CKD & cirrhosis, covered in Ontario No Time to Relax about Liver Cancer after HCV Treatment: Time to Change Monitoring
Finally, Maviret, AbbVie's hepatitis C drug, has made it through Canada's approval process and has been listed for coverage by Ontario's PharmaCare. We hope BC PharmaCare will also list it soon. "MAVIRET™ is the first and only 8-week, pan-genotypic treatment for chronic hepatitis C patients without cirrhosis and who are new to treatment (from: Decisions Resources Group. Hepatitis C virus: disease landscape & forecast 2016 and 2017)... MA...
Funding of up to $2500 is available to support women's self-directed health and education ideas...to improve health, wellness, skills building and social connectivity." More Information at... https://www.vancouverfriendsforlife.ca/women-s-welleness-project First deadline: March 15, 2019 (results announced March 30th)
Current protocols for HCV post-SVR monitoring may need updating to expand screening for liver cancer to those without cirrhosis. This article is dedicated to all non-cirrhotics who have been diagnosed with liver cancer following treatment for HCV. HepCBC's volunteer Webmaster, CD Mazoff, PhD (discourse analysis, McGill), is battling liver cancer (HCC). For several years, CD has faithfully published the online HepCBC Weekly Bull every Friday, showcasing Ca